Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The portfolio, purchased from a leading multinational generic manufacturer, addresses a market valued at $473.2 million for the 12 months ending August 2025
NUFYMCO BLA has been approved by the USFDA
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
The product will be marketed by Dr. Reddy's Laboratories Inc.
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Abdomen-pelvis CT is the nation’s highest-volume CT category
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Subscribe To Our Newsletter & Stay Updated
